Presentation is loading. Please wait.

Presentation is loading. Please wait.

Ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen for the management of endometriosis-associated pelvic pain: a randomized controlled.

Similar presentations


Presentation on theme: "Ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen for the management of endometriosis-associated pelvic pain: a randomized controlled."— Presentation transcript:

1 Ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen for the management of endometriosis-associated pelvic pain: a randomized controlled trial  Tasuku Harada, M.D., Saori Kosaka, M.D., Joerg Elliesen, M.D., Masanobu Yasuda, Makoto Ito, Mikio Momoeda, M.D.  Fertility and Sterility  Volume 108, Issue 5, Pages (November 2017) DOI: /j.fertnstert Copyright © 2017 The Authors Terms and Conditions

2 Figure 1 Patient flow during the double-blind treatment phase (week 24) and the open-label extension phase (week 52) of the study (full analysis set [FAS]). Fertility and Sterility  , DOI: ( /j.fertnstert ) Copyright © 2017 The Authors Terms and Conditions

3 Figure 2 (A) Reduction from baseline to week 24 in pain measures associated with endometriosis; (B) gynecologic endpoints. Fertility and Sterility  , DOI: ( /j.fertnstert ) Copyright © 2017 The Authors Terms and Conditions


Download ppt "Ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen for the management of endometriosis-associated pelvic pain: a randomized controlled."

Similar presentations


Ads by Google